Price Adjustments Announced for 32 Pharmaceutical Products, Including Drugs from Qilu Pharma, Zhengda Tianqing, and Eli Lilly

Apr 07, 2021 11:26 CST Updated 11:26

Qilu Pharmaceutical

Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer

Eli Lilly

Global Pharmaceutical R&D and Production Company

Patheon Italia SpA

Pharmaceutical Development and Manufacturing

Innovent

High-end Biologics Developer

NJCTTQ

Major Pharmaceutical R&D Company

On April 6, the Jiangsu Provincial Public Resource Trading Center issued a notice on adjusting the supply prices of certain pharmaceutical products. The notice indicated that the supply prices for 32 drug specifications were reduced. These include tadalafil tablets from Qilu Pharmaceutical and SUNCADIA, ixekizumab injection from Eli Lilly, bivalirudin for injection from Patheon Italia SpA and Qilu Pharmaceutical, vildagliptin tablets from China Resources Saike Pharmaceutical Co., Ltd., bevacizumab injection from Innovent Bio, tofacitinib citrate tablets from Chia-TaiTianqing, and apixaban tablets, among others.

The specific price adjustments are as follows:

*Disclaimer: This article was written by an author contributing to Sina Medical News. The views expressed are solely those of the author and do not represent the position of Sina Medical News.